✦ LIBER ✦

Enhanced pulmonary toxicity with bleomycin and radiotherapy in oat cell lung cancer

✍ Scribed by Lawrence Einhorn; Maurice Krause; Ned Hornback; Becky Furnas

Publisher: John Wiley and Sons
Year: 1976
Tongue: English
Weight: 269 KB
Volume: 37
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(197605)37:5<2414::aid-cncr2820370533>3.0.co;2-j

No coin nor oath required. For personal study only.

✦ Synopsis

In a recently completed study, combination chemotherapy consisting of bleomycin, adriamycin, cyclophosphamide, a n d vincristine was given to 29 patients with oat cell lung cancer. There were no cases of pulmonary fibrosis in these 29 patients. Although several of these patients had prior radiotherapy, none had concomitant radiotherapy and chemotherapy. This same four-drug chemotherapy regimen was combined with concomitant radiotherapy in 13 patients with oat cell lung cancer. There were three cases of fatal pulmonary fibrosis and two other cases of clinically significant pulmonary fibrosis. All five cases of pulmonary fibrosis occurred several weeks after completion of a six-week course of bleomycin (total dosage 90 units). It is concluded that bleomycin cannot be safely administered while patients are receiving radiotherapy to the lung.

📜 SIMILAR VOLUMES

Decreased metastasis and improved surviv

Decreased metastasis and improved survival with early thoracic radiotherapy and prophylactic cranial irradiation in combined-modality treatment of limited-stage small cell lung cancer

✍ Sachin S. Kamath; Dean L. McCarley; Robert A. Zlotecki 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB 👁 2 views

In an attempt to verify the relative efficacy of early concurrent vs. sequential timing of thoracic radiotherapy (TRT) and platinum/etoposide chemotherapy, 48 patients with limited-stage small cell lung cancer treated with either early-concurrent (29 patients) or sequential (19 patients) TRT and pla

Results of a phase II concurrent chemora

Results of a phase II concurrent chemoradiotherapy study using three-dimensional conformal radiotherapy with cisplatin and oral etoposide in stage III nonsmall-cell lung cancer

✍ L.M. Chen; L. Ignacio; R. Jacobs; M. Kozloff; M. Telfer; R. Elahi; R. Evans; S. 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 127 KB 👁 2 views

CD80 expression in an HLA-A2-positive hu

CD80 expression in an HLA-A2-positive human non-small cell lung cancer cell line enhances tumor-specific cytotoxicity of HLA-A2-positive T cells derived from a normal donor and a patient with non-small cell lung cancer

✍ Dale L. Bixby; John R. Yannelli 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 French ⚖ 185 KB 👁 2 views

To generate non-small cell lung cancer (NSCLC)-reactive lymphocytes, we transfected an HLA-A2-expressing human NSCLC line (1355) with the cDNA encoding the lymphocyte co-stimulatory molecule CD80. Following selection in G418, 1355.7 demonstrated stable cell-surface expression of CD80. Allogeneic mix